Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-24-Speech-3-965"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20101124.15.3-965"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Approval of the new legislation on information on medicinal products represents a further step toward guaranteeing patients clearer and more effective information on the drugs they take and are prescribed.
We need a harmonised legal framework at European level that not only maintains the ban on advertising medicinal products subject to medical prescription but also takes into account the patient’s right to information. This is no small matter, because the sometimes blurred boundary between ‘product promotion’ and ‘product information’ is liable to confuse patients.
We must remember that patients are playing a more and more active role in the health sector throughout the European Union. Better access to non-promotional information may therefore help the public to gain a better understanding of the treatments prescribed to them and help their recovery, all naturally in the interests of their health.
To conclude, I would like to underscore the importance of defining in a transparent way the types of information on drugs and the channels through which such information may be disseminated. We must reduce the risk of disguised advertising and, where necessary, the risk of a surfeit of uncontrolled and misleading information."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples